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Abstract 
 
Background and purpose 
Papillon treatment is a form of contact X-ray brachytherapy (CXB) which is used as an alternative to 
surgery for rectal cancer. This study aimed to audit patients who were referred for and treated with 
CXB over a 6 year period against guidelines derived from a critical review of the evidence base.   
 
Materials and methods: 
Patient demographics, tumour characteristics, and outcome data were gathered for 31 patients 
referred for CXB. A critical review of the evidence identified consensus referral criteria and outcome 
data against which to audit patients. 
 
Results:  
Referral criteria were derived from six published studies. These applied to patients unfit for surgery 
or stoma-averse. All referred patients had a visible tumour or scar with a tumour size under 3cm and 
sited less than 12cm from the anal verge. Nodal status varied from N0 to N2 but there was no 
metastatic disease present. The audited cohort demonstrated demographic equivalence while initial 
clinical complete response and recurrence rates were also comparable. 
 
Conclusion:  
This audit confirmed the validity of referral and treatment protocols and should guide future referrals 
until evidence from ongoing studies becomes available. These findings should contribute to 
development of robust national guidelines.
 
 
Introduction 
The ‘Papillon’ technique of contact X-ray brachytherapy (CXB) uses 50kV X-rays to deliver up to 30 Gy 
per fraction to treat early stage rectal tumours. It is delivered fortnightly over 3 or 4 fractions, via a 
treatment rectoscope under direct vision using dedicated machines such as the Papillon 50 (Ariane, 
Alfreton, UK). The technique is associated with no mortality and very little morbidity,[1] aside from 
short-term bleeding in around 26% of patients. [2] Although the technique has been around for over 
80 years, it has recently seen a resurgence in the UK as a viable treatment option. Colorectal cancers 
are currently the 4th most common in type of cancer in England, with 27% of these being rectal cancers. 
[3] The number of these patients deemed suitable for CXB is increasing due to improved availability 
of CXB in the UK and increased early detection from screening. [4,5] 
 
The National Institute for Health and Care Excellence (NICE) currently only supports use of this 
procedure for early-stage rectal cancer for whom surgery is unsuitable or has been declined [6] due 
to a lack of high quality evidence regarding efficacy. Although there is currently only one level 1b 
randomised controlled trial (RCT) for CXB, the phase 3 OPERA trial is currently open. [7] The current 
gold standard for treating rectal cancer is surgery, which has considerable mortality and morbidity for 
elderly patients [8] and results in a permanent stoma in about a third of patients. [2]  Avoidance of a 
permanent stoma is an important outcome measure with great impact on patient quality of life (QoL). 
[9]) The need for a standardised set of criteria to guide CXB referral is becoming essential, yet the 
dearth of published data means that centres are instead relying on clinician experience and expertise.   
 
The aim of this audit is to assess whether the correct categories of patients were referred for CXB 
treatment from a major cancer centre. Results from this audit could inform and guide future referral 
choices. The lack of guidelines meant that published data had to be collated to provide a standard for 
comparison. Referral guidelines are an important aspect of evidence-based practice and this paper 
aimed to highlight key referral criteria to help inform this. 
 
Methods 
This study required a two-phase approach commencing with a preliminary literature review gathering 
published data in lieu of national guidelines. The second phase comprised an audit of referral patterns 
and outcomes against the published data.  
 
Phase One: Literature Review 
A search utilising variations and combinations of the keywords “Papillon therapy” and “Rectal cancer” 
was performed throughout the Medline, Scopus and Web of Science databases using the inclusion 
and exclusion criteria summarised in Table 1. Screening and quality assessment were performed as 
per the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [10] guidelines 
and summarised in Figure 1. The remaining papers were considered the most relevant and highest 
quality evidence available to be included in the review.  These were then analysed to extract patient 
and tumour characteristics data and outcome data for the cohort treated in each study. Outcome data 
comprised median follow-up, initial complete clinical response (cCR) rate, local recurrence rate after 
cCR (including after salvage surgery), local control after cCR, rate of distant metastases, and overall 
survival. 
 
Phase Two: Audit 
 
 
The patient cohort comprised patients referred and treated with CXB between 2013 and 2019. 
Extracted data included TNM staging, tumour location and differentiation, patient age and 
performance status.  Dates and results of most recent radiological assessment were also included, 
along with cause of death (where appropriate) and any additional treatment received if local or distant 
progression was developed. Rationale for patient referral was extracted to identify those who were 
not suitable for surgery or wanted to avoid a stoma.  All referred patients received CXB treatment at 
another regional centre and the treatment was delivered according to departmental protocol. This 
consisted of 30 Gy of 50-kV X-rays delivered at each visit, using a Papillon 50 machine, as an outpatient 
every two weeks, with most patients receiving a total of 90 Gy delivered in 3 fractions over 4 weeks. 
[11] All patients were also prescribed either short-course radiotherapy of 25 Gy in 5 fractions over 5 
days or long-course radiotherapy of 45 Gy in 25 fractions over 35 days, with or without concurrent 
chemotherapy. Palliative patients were excluded from the cohort to ensure accurate comparison with 
the published data. The project was approved by the Clinical Governance Committee as a 
retrospective audit with no requirement for ethical clearance.  
 
Results 
 
Development of criteria  
Referral and outcome data was gathered from five papers relating to six cohorts as summarised in 
Tables 2 and 3. All five of the included papers agreed that to be eligible for Papillon treatment, the 
patient must have a visible tumour or post-excision scar as a target at which to direct the CXB boost. 
[11,12] Tumours from stage Tis-T4 were all treated across the five studies, with the main limitation 
mentioned being the size of the tumours, as bulkier tumours are difficult to treat due to a limitation 
arising from the maximum physical size of the treatment applicator.[13] Three of the five papers 
agreed that the maximum tumour size treatable with CXB was 3 cm [11,13,15], whereas two treated 
larger tumours; one treating up to 4 cm [12] and the other did not specify a maximum size, but 
explained tumours over 3 cm were treated using overlapping fields.  All papers agreed that patients 
with tumours larger than their maximum size treated by CXB could have external beam radiotherapy 
tumour debulking prior to CXB dose boost. All studies included patients with and without nodal 
involvement at the time of diagnosis (N0-N2). The maximum distance from the anal verge of the 
tumour treated by CXB was either ≤ 10 cm [12,15] or ≤ 12 cm. [11,13,14] 
 
Where the information was given (n=4), all papers treated well to poorly differentiated tumours, with 
the majority of tumours well or moderately differentiated. [11-13,15] Similarly, the same papers 
included performance status (PS) of patients (n=3) and treated patients of any PS (PS0-3). No patients 
with metastatic disease were included in any of the studies, though 3 of the papers did state that 
patients with M1 disease and other patients which could not be treated with curative intent were 
treated palliatively using CXB. [11,13,15] The median age of patients across the studies was 
comparable with a wide age range of 30-94 across all studies. 
 
All papers included patients with inoperable tumours, those opted against surgery due to the 
associated morbidity and possible mortality, and those that refused a stoma.  Though not all studies 
included how many operable patients were treated with CXB, 4 out of the 5 papers indicated that the 
majority of patients treated were operable, with CXB treatment chosen to increase the chance of 
organ preservation and stoma avoidance. [12-15]   
 
 
 
The limited number of papers reflects the fact that Papillon technique is not regarded as a standard 
of care for rectal cancer, with only 4 centres in the UK currently offering CXB. [16] All the papers 
suffered from the same limitation of being retrospective studies which may have some degree of 
selection bias. Despite these shortcomings, all papers met the inclusion criteria and, due to the lack of 
any large multicentre randomised trial, represent the highest quality of relevant evidence available at 
this time. From these results, a list of criteria for radical intent CXB treatment was derived for the audit 
as shown in Table 4. 
 
Audit results: Patient characteristics 
Over the audit period 45 patients were referred for CXB treatment; of these, 5 were excluded as they 
were still undergoing Papillon treatment, and 9 were excluded as they were being treated with 
palliative intent.  A study size of 31 patients may be considered a relatively small cohort, but two of 
the comparator cohorts had similar numbers (n=40, n=45) and one had fewer (n=17). Patient 
demographics can be seen in Table 2; the median age of patients referred was 73, which was within a 
year of the median age of four of the six cohorts.  Of the other two cohorts, one had a higher median 
age and one was lower.  Gender ratio was similar across all studies, with male being the majority in all 
of them.  Performance status was not included in all published data, although most patients were PS 
0-1, which matched with the audit cohort. One of the criteria for referral identified above was that 
the patient was unsuitable for surgery or had refused surgery to avoid a stoma. Only two of the studies 
included the proportion of patients who were considered operable, so this data was not included in 
Table 2. The audit cohort identified 42% of patients as unfit for surgery, compared to 57% described 
as either inoperable or high risk in one study [12] and 27% described as inoperable in another. [15]  
 
Audit results: Tumour characteristics 
Differentiation of tumour data was available in five of the six cohorts.  However, in all five of these a 
significant proportion was not known (17.7%-31.5%). The majority of the audited cohort presented 
with moderately differentiated tumours (96.8%) which was higher than all the comparators, although 
in all cohorts, well to moderate differentiation was the majority. The audit cohort had pre-treatment 
tumour stages between T1 and T3, while most of the tumours in all cohorts were stage T2 or T3. Nodal 
status was predominantly N0 in all studies with the audited cohort reporting 83.9% N0 nodal stage.  
No patients with metastatic disease were included in any of the cohorts. 
 
Audit results: Outcome data 
Median follow-up of all seven cohorts ranged from 20 months to 64 months with the audit cohort 
towards the shorter end at 22 months.  Initial complete clinical response (cCR), local recurrence (LR), 
sustained local control (LC), metastatic spread and overall survival (OS) rates were compared. An 
‘initial cCR’ was defined as following CXB but before any necessary salvage surgery.  The rate of initial 
cCR for the audit cohort was high at 93.6%; this was similar to three of the six comparator groups. The 
LR rate after cCR included recurrence in all patients considered to have achieved a cCR following CXB 
and any necessary salvage surgery. A total of 20.7% of the audit cohort experienced local recurrence 
for which no further treatment was possible; this was comparable to the reported rates which ranged 
from 11%-27%. Sustained LC in the audit cohort was achieved for 25 of the 31 (80.6%) patients 
referred for CXB which is similar to two of these comparator cohorts with the other three cohorts 
reporting both higher and lower rates (60%-95%).  The rate of distant metastases was relatively low 
 
 
within the reported data, ranging from 8.5%-20.5%, while the audit cohort rate was 13.8%.  Finally, it 
was encouraging to see the audit cohort reporting the highest rate of OS at 83.9%, with one study 
reporting a similar rate of 82%  [14] and the others ranging from 60%-73%. Figure 2 shows the Kaplan-
Meier plot for this within the studied cohort.  
 
Discussion 
 
Referral criteria 
The different distribution of tumour (T) stage across the published evidence can partly be attributed 
to selectivity of studies with papers only reporting a specific cohort.  However, and importantly for 
the validity of the outcome data, two papers found that stage of tumour was not a prognostic factor 
for achieving a cCR or for survival. [11,13] Similarly, though nodal stage of patients was distributed 
differently in the audit cohort, with more N0 than other studies, this was also found to not be related 
to chance of achieving a cCR or local regrowth rates. [11,13]  
 
Whilst performance status and age in the audit cohort was similar to the other studies, it did include 
more PS 0 patients than any of the other studies.  Though PS and age were not found to be indications 
for cCR rate (11), one paper did report them as factors for disease-free survival (both p = <0.001). [13] 
This possibly reflected the median age and thus likelihood of patient comorbidities as well as patient 
tolerance to external beam radiotherapy. [17] It is likely, therefore, this higher proportion of PS 0 
patients might have contributed to the higher OS reported in the audit cohort. 
 
Underlying rationale for referral proved challenging to audit for several reasons. Firstly, not all of the 
studies included this data, despite all of them indicating that one of the main reasons for a CXB boos 
was to improve the rate of organ preservation and reduce permanent stoma risk. [11-15] Secondly, 
the criteria for patients either being unfit for surgery or inoperable were unclear and may have been 
reported differently for each study. This is a limitation for the study as having a higher proportion of 
operable patients who can undergo possible salvage surgery may improve overall local control rates 
for that cohort. 
 
Overall, the patient and tumour characteristics of the audit cohort were similar in many ways to those 
of the cohorts reported in the published data.  This suggested that, based on these criteria, referrals 
within the audit aligned well with current best evidence. This also indicated that comparison of 
outcome data would be valid. 
 
Patient outcomes 
Though cCR was used for comparing outcomes, the exact method and criteria used for assessing this 
was not explained well in all the papers and may have even changed with time or investigator 
expertise.  This issue was acknowledged and within another recent paper which described how to 
accurately assess response to CXB. [18]  This possible limitation may explain the difference in initial 
cCR rates reported across the studies.    
 
Local recurrence rate was similar across all seven cohorts, which is significant because this was found 
to be independent of PS, age, tumour stage, nodal stage, distance from anal verge, tumour size or 
treatment method. [13] The rate of distant metastases was higher in all of the studies with longer 
 
 
follow-up lengths, which may indicate time could be a factor for this outcome, however one study 
with a longer follow-up time had a lower rate of distant metastases than the audit cohort.  
 
Although it was difficult to make an accurate comparison of outcome data for all the reasons explored 
above, many of the outcomes of the audit cohort were comparable to published studies, especially LR 
after cCR, which reaffirms referral criteria. It is recommended that the audit be repeated after a longer 
follow-up period to ensure the outcome comparisons remain valid.  Further work will also include 
stoma-free survival and bowel function data for all patients treated with CXB as this is highlighted in 
the literature as an important outcome and one of the main reasons that CXB is used over non-
conservative surgical treatment.  Like other recent studies have noted, evidence suggests that CXB 
treatment is indicated as a good, potentially organ preserving alternative to surgery for older, co-
morbid patients who are inoperable or high surgical risk, as well as younger, stoma-averse patients, 
and has good cCR and LR rates. [11-13] It is recommended that the national guidelines be updated to 
reflect this growing body evidence. 
 
Limitations 
As well as the limitations described above, this study has several other constraints.  Firstly, as this 
study was a retrospective audit, only data available at the time of review could be used. This data may 
include an unknown number of referred patients who were deemed unsuitable and rejected by the 
treating department.  Criteria development was based on the strongest available current evidence but 
all studies used had their own acknowledged limitations. In general these were selective, 
retrospective, monocentric reviews over time periods where treatment techniques, assessment 
methods, and equipment may have changed.   
 
Conclusion  
The results of this audit demonstrated that the demographic and pathological profile of the referred 
patients matched those reported in the literature. The similarity of the cohorts enabled comparison 
of outcome data which confirmed the validity of referral and treatment protocols. Although the 
limited evidence base and retrospective nature of the audit limits the strength of the findings, this 
work should guide future referrals until evidence from ongoing studies becomes available and can also 
be used to inform future audits undertaken in this area. It is also anticipated that the reviewed 
evidence presented here will contribute to development of robust national guidelines.  
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Table 1: Literature review inclusion and exclusion criteria 
 
Inclusion Criteria Exclusion Criteria 
English language 
2008 onwards 
Full article available 
Relates to radical CXB  
Includes patient referral data 
Includes outcome data 
Lack of a patient cohort 
Abstracts only 
Any CXB not used to treat rectal cancer 
 
 
Table 2: Comparison of referral data 
 
  Audit  Myint 
2018 
[11] 
Frin 
2017 
[12] 
Myint 
2017 
[13] 
Smith 
2016 
[14] 
Gerard 
2015 
[15] 
Gerard 
2015 [15] 
Cohort size (n) 31 83 45 200 17 80 40 
Median age Years 73 72 74 74 65 73 81 
Age range Years 47-90 36-87 30-93 32-94 47-84 NR NR 
Gender Females 32.3% 30.1% 28.8% 33.0% 11.8% 30% 27.5% 
Males 67.7% 69.9% 71.1% 67.0% 70.6% 70% 72.5% 
NR 0 0 0 0 17.6% 0 0 
Performance 
Status 
0 54.8% 42.2% - 33.0% -  
48.6% 
 
77.5% 1 22.6% 41.0% - 36.5% - 
2 19.4% 10.8% - 20.5% -  
30% 
 
22.5% 3 3.2% 3.6% - 3.5% - 
NR 0 2.4% 100% 6.5% 100% 21.3% 0 
Differentiation Well 0 3.6% 40% 5.0% - 45% 35% 
Moderate 96.8% 69.9% 37.7% 60.5% - 28.8% 40% 
Poor 3.2% 1.2% 4.4% 3.0% - 3.8% 5% 
NR 0 25.3% 17.7% 31.5% 100% 22.5% 20% 
Tumour stage  T1 19.4% 0 4.4% 10.5% 11.8% 5% 7.5% 
T2 41.9% 33.7% 51.1% 44.5% 17.6% 60% 47.5% 
T3 38.7% 66.3% 44.5% 43.5% 47.0% 35% 45.0% 
T4 0 0 0 1.5% - 0 0 
NR 0 0 0 0 17.6% 0 0 
Nodal stage N0 83.9% 45.8% 73.3% 62.5% 41.2% 75% 72.5% 
N1 16.1% 38.6% 22.2% 28.0% 11.8% 25% 27.5% 
N2 0 14.5% 4.5% 9% 23.5% 0 0 
NR 0 1.2% 0 0.5% 17.6% 0 0 
Metastases M0 100% 100% 100% 100% 100% 100% 100% 
Key: NR = not reported or unknown 
 
 
 
 
Table 3: Comparison of outcome data 
 
 Audit 
cohort 
Myint 
2018 [11] 
Frin 2017 
[12] 
Myint 
2017 [13] 
Smith 2016 
[14] 
Gerard 
2015 [15] 
Gerard 
2015 [15] 
Cohort 
size 
31 83 45 200 17 80 40 
Median 
FU 
22  
months 
30 months 60 months 32 months 20 months 64 months 63 months 
FU 
range  
4-55 
months 
14-100 
months 
NR NR 5-54 
months 
NR NR 
cCR 29 
(93.6%) 
53 (64.8%) 43 (96%) 144 (72%) 9 (53%) 75 (94%) 38 (95%) 
LR 6 
(20.7%) 
6 (11.4%) 11% 16 (11%) NR 22 (27%) 4 (14%) 
LC  25 
(80.6%) 
69 (83.1%) NR 80.5% 60% 73% 95% 
Mets 4 
(13.8%) 
7 (13.2%) 17% 17 (8.5%) NR 10 (17%) 8 (20.5%) 
OS 26 
(83.9%) 
56 (67.5%) 64% at 3-
years 
136 (68%) 82% 73% 60% 
Key: FU = Follow-up; cCR = Initial complete clinical response; LR = Local recurrence after cCR (including after 
salvage); LC = Local control;  Mets = Presence of distant metastases; OS = Overall survival 
 
 
 
 
Table 4: Criteria for radical intent CXB treatment 
 
Patient unfit for surgery or stoma-averse 
Visible tumour or post-excision scar 
Tumour size < 3cm (following debulking radiotherapy) 
Tumour sited < 12cm from anal verge 
Nodal status N0-N2 
Tumour well to poorly differentiated 
No metastatic disease 
 
 
  
 
 
Figure 1: PRISMA diagram summarising evidence collection 
 
 
 
Figure 2: Kaplan-Meier plot of Overall Survival  
 
 
 
 
